Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03171935
Other study ID # BeijingCYH-ICU-005
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2017
Est. completion date March 31, 2022

Study information

Verified date June 2021
Source Beijing Chao Yang Hospital
Contact Zujin Luo, MD
Phone 10-86-51718564
Email xmjg2002@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of the present study is to verify whether, as compared with conventional weaning, early weaning with high-flow nasal cannula oxygenation or noninvasive positive pressure ventilation may more effective in shortening the duration of invasive ventilation, hence reducing the rates of complications and mortality in patients with acute hypoxemic respiratory failure.


Recruitment information / eligibility

Status Recruiting
Enrollment 270
Est. completion date March 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Orotracheal intubation; 2. PaO2 <60mmHg(venturi mask,FiO2=0.5),and PaCO2 =45mmHg; 3. Meeting criteria for weaning readiness; 4. Spontaneous breathing trial failure. Exclusion Criteria: 1. Age<18; 2. Duration of invasive ventilation <48h; 3. Tracheotomy; 4. Percentage of cuff leak volume in tidal volume<15.5%; 5. Unable to spontaneously clear secretions from their airway; 6. Recent oral,nasal,facial or cranial trauma or surgery; 7. Recent gastric or esophageal surgery; 8. Active upper gastro-intestinal bleeding; 9. Severe abdominal distension; 10. Lack of co-operation; 11. Chronic respiratory disease such as chronic obstructive pulmonary disease, asthma, interstitial lung disease and neuromuscular disease.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
High-Flow Nasal Cannula Oxygenation
High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
Noninvasive Positive Pressure Ventilation
Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 >92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 >96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
Conventional weaning
The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.

Locations

Country Name City State
China Beijing Institute of Respiratory Medicine, Department of respiratory and critical care medicine, Beijing Chao-Yang Hospital Jingxi Campus, Capital Medical University Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Chao Yang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of invasive mechanical ventilation 2.5 years